Conventional lactate-buffered peritoneal dialysis (PD) solutions have several bioincompatible characteristics, including acidic pH, lactate buffer, and the presence of glucose degradation products (GDPs). These characteristics, along with inflammation, are believed to contribute to membrane dysfunction in peritoneal dialysis patients. A new PD solution containing a bicarbonate/ lactate buffer system with physiologic pH and low GDPs has shown improved biocompatibility in both in vitro and ex vivo studies. In the present study, the concentrations of cytokines interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα), and vascular endothelial growth factor (VEGF), were measured in timed overnight effluents from PD patients continuously dialyzed with either lactate-based control solution (C) or bicarbonate/lactate–based solution (B/L) for 6 months.
♦ Methods
Effluents from 92 continuous ambulatory peritoneal dialysis (CAPD) patients were collected when the patients were entered into the study (baseline, all patients on C for more than 3 months), and at 3 and 6 months following randomization to C (n = 31) or to B/L (n = 61). Effluent samples were filtered, stored frozen, and then assayed for IL-6, TNFα, and VEGF by ELISA.
♦ Results
A significant decrease in effluent IL-6 was seen at 3 months and at 6 months in the B/L-treated patients. Levels of VEGF were significantly reduced at 3 months. No changes in the levels of IL-6 or VEGF were seen in the C-treated patients, and no changes in TNFα were seen in either group over time.
♦ Conclusions
Treatment with B/L is associated with decreased IL-6 synthesis and decreased VEGF secretion. The data suggest that the use of B/L solution is associated with reduced intraperitoneal inflammation and potential for angiogenesis. The use of B/L solution may, over time, help to restore peritoneal homeostasis and therefore preserve the function of the membrane in peritoneal dialysis.
LaiK.N., LaiK.B., SzetoC.C., LamC.W., LeungJ.C.Growth factors in continuous ambulatory peritoneal dialysis effluent. Their relation with peritoneal transport of small solutes.Am J Nephrol1999; 19(3): 416–22.
5.
YamagataK., TomidaC., KoyamaA.Intraperitoneal hyaluronan production in stable continuous ambulatory peritoneal dialysis patients.Perit Dial Int1999; 19(2): 131–7.
6.
ZweersM.M., de WaartD.R., SmitW., StruijkD.G., KredietR.T.Growth factors VEGF and TGF-beta1 in peritoneal dialysis.J Lab Clin Med1999; 134(2): 124–32.
7.
GoldmanM., VandenabeeleP., MoulartJ., AmraouiZ., AbramowiczD., NortierJ.Intraperitoneal secretion of interleukin-6 during continuous ambulatory peritoneal dialysis.Nephron1990; 56(3): 277–80.
8.
LaiK.N., LaiK.B., LamC.W., ChanT.M., LiF.K., LeungJ.C.Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis.Am J Kidney Dis2000; 35(4): 644–52.
9.
ZemelD., ImholzA.L., de WaartD.R., DinklaC., StruijkD.G., KredietR.T.Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD.Kidney Int1994; 46(5): 1422–30.
ThomasK.A.Vascular endothelial growth factor, a potent and selective angiogenic agent.J Biol Chem1996; 271(2): 603–6.
12.
TranæusA.A long-term study of a bicarbonate/lactate– based peritoneal dialysis solution—clinical benefits. the Bicarbonate/Lactate Study Group.Perit Dial Int2000; 20(5): 516–23.
13.
TopleyN., WilliamsJ.D.Role of the peritoneal membrane in the control of inflammation in the peritoneal cavity.Kidney Int1994; 46(Suppl 48): S71–8.
14.
TopleyN., JörresA., LuttmannW., PetersenM.M., LangM.J., ThierauchK.H.Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1β and TNF-α.Kidney Int1993; 43: 226–33.
15.
LanfranconeL., BoraschiD., GhiaraP., FaliniB., GrignaniF., PeriG.Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor [CSF], granulocyte–monocyte–CSF, macrophage–CSF, interleukin-1 [IL-1], and IL-6) and are activated and stimulated to grow by IL-1.Blood1992; 80(11): 2835–42.
16.
JacobsonA., BrinckJ., BriskinM.J., SpicerA.P., HeldinP.Expression of human hyaluronan synthases in response to external stimuli.Biochem J2000; 348(Pt 1): 29–35.
RippeB., SimonsenO., HeimbürgerO., ChristenssonA., HaraldssonB., StelinG.Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Kidney Int2001; 59(1): 348–57.
19.
CarozziS., NasiniM.G., RaveraM., SannaA., TirottaA., LamperiS.Peritoneal dialysis effluent, cytokine levels, and peritoneal mesothelial cell viability in CAPD: a possible relationship.Adv Perit Dial1997; 13: 7–12.
20.
JonesS.A., HoriuchiS., TopleyN., YamamotoN., FullerG.M.The soluble interleukin 6 receptor: mechanisms of production and implications in disease.FASEB J2001; 15(1): 43–58.
21.
SchindlerR., MancillaJ., EndresS., GhorbaniR., ClarkS.C., DinarelloC.A.Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF.Blood1990; 75(1): 40–7.
22.
HurstS.M., WilkinsonT.S., McLoughlinR.M., JonesS., HoriuchiS., YamamotoN.IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation.Immunity2001; 14(6): 705–14.
23.
StenvinkelP.Inflammatory and atherosclerotic interactions in the depleted uremic patient.Blood Purif2001; 19(1): 53–61.
24.
MacKenzieR.K., HolmesC.J., MoseleyA., JenkinsJ.P., WilliamsJ.D., ColesG.A.Bicarbonate/lactate– and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNF-alpha secretion.J Am Soc Nephrol1998; 9(8): 1499–506.
25.
MackenzieR.K., JonesS., MoseleyA., HolmesC.J., ArgyleR., WilliamsJ.D.In vivo exposure to bicarbonate/lactate– and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function.Am J Kidney Dis2000; 35(1): 112–21.
26.
CombetS., MiyataT., MoulinP., PouthierD., GoffinE., DevuystO.Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis.J Am Soc Nephrol2000; 11(4): 717–28.
27.
InagiR., MiyataT., YamamotoT., SuzukiD., UrakamiK., SaitoA.Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis.FEBS Lett1999; 463(3): 260–4.
28.
HondaK., NittaK., HoritaS., YumuraW., NiheiH.Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure.Nephron1996; 72(2): 171–6.
29.
HondaK., NittaK., HoritaS., YumuraW., NiheiH., NagaiR.Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration.Nephrol Dial Transplant1999; 14(6): 1541–9.
30.
MateijsenM.A., van der WalA.C., HendriksP.M., ZweersM.M., MulderJ., StruijkD.G.Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis.Perit Dial Int1999; 19(6): 517–25.
